首页> 美国卫生研究院文献>Oncotarget >Solid formulation of a supersaturable self-microemulsifying drug delivery system for valsartan with improved dissolution and bioavailability
【2h】

Solid formulation of a supersaturable self-microemulsifying drug delivery system for valsartan with improved dissolution and bioavailability

机译:用于缬沙坦的过饱和自微乳化药物递送系统的固体制剂具有改善的溶解度和生物利用度

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In order to improve the dissolution and oral bioavailability of valsartan (VST), and reduce the required volume for treatment, we previously formulated a supersaturable self-microemulsifying drug delivery system (SuSMEDDS) composed of VST (80 mg), Capmul® MCM (13.2 mg), Tween® 80 (59.2 mg), Transcutol® P (59.2 mg), and Poloxamer 407 (13.2 mg). In the present study, by using Florite® PS-10 (119.1 mg) and Vivapur® 105 (105.6 mg) as solid carriers, VST-loaded solidified SuSMEDDS (S-SuSMEDDS) granules were successfully developed, which possessed good flow properties and rapid drug dissolution. By introducing croscarmellose sodium (31 mg) as a superdisintegrant, S-SuSMEDDS tablets were also successfully formulated, which showed fast disintegration and high dissolution efficiency. Preparation of granules and tablets was successfully optimized using D-optimal mixture design and 3-level factorial design, respectively, resulting in percentage prediction errors of <10%. In pharmacokinetic studies in rats, the relative bioavailability of the optimized granules was 107% and 222% of values obtained for SuSMEDDS and Diovan® powder, respectively. Therefore, we conclude that novel S-SuSMEDDS formulations offer great potential for developing solid dosage forms of a liquefied formulation such as SuSMEDDS, while improving oral absorption of drugs with poor water solubility.
机译:为了改善缬沙坦(VST)的溶出度和口服生物利用度并减少所需的治疗量,我们先前配制了由VST(80 mg),Capmul ®组成的过饱和自微乳化药物递送系统(SuSMEDDS) MCM(13.2 mg),Tween ® 80(59.2 mg),Transcutol ® P(59.2 mg)和泊洛沙姆407(13.2 mg)。在本研究中,通过使用Florite ® PS-10(119.1 mg)和Vivapur ® 105(105.6 mg)作为固体载体,负载VST的固化SuSMEDDS(S- SuSMEDDS)颗粒被成功开发,具有良好的流动性和快速的药物溶解。通过引入交联羧甲基纤维素钠(31 mg)作为超级崩解剂,还成功配制了S-SuSMEDDS片剂,该片剂显示出快速崩解和高溶解效率。分别使用D-最佳混合物设计和三级因子设计成功优化了颗粒和片剂的制备,导致百分比预测误差<10%。在大鼠的药代动力学研究中,优化后的颗粒的相对生物利用度分别是SuSMEDDS和Diovan ®粉末获得的值的107%和222%。因此,我们得出结论,新型S-SuSMEDDS制剂为开发液化制剂(例如SuSMEDDS)的固体剂型提供了巨大的潜力,同时改善了水溶性差的药物的口服吸收。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号